Background Trastuzumab emtansine (T-DM1) is an antibody–drug conjugate incorporating
the human epidermal growth factor receptor 2 (HER2)–targeted antitumor properties of …

Background Growth of hormone-receptor–positive breast cancer is dependent on cyclin-dependent
kinases 4 and 6 (CDK4 and CDK6), which promote progression from the G1 phase …

Background Trastuzumab emtansine is the current standard treatment for patients with
human epidermal growth factor receptor 2 (HER2)–positive metastatic breast cancer whose …

Background The inhibition of cyclin-dependent kinases 4 and 6 (CDK4/6) could potentially
overcome or delay resistance to endocrine therapy in advanced breast cancer that is positive …

Background In the PALOMA-3 study, the combination of the CDK4 and CDK6 inhibitor
palbociclib and fulvestrant was associated with significant improvements in progression-free …

Background The cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor palbociclib, in
combination with fulvestrant therapy, prolongs progression-free survival among patients with …

The COVID-19 pandemic has been instrumental in creating a dramatic shift from people's
need to live in mutual association toward a desire to stigmatize distinctive others. Pandemic …

Background The antibody–drug conjugate trastuzumab emtansine is indicated for the
treatment of patients with HER2-positive metastatic breast cancer previously treated with …

Neuropathic pain arises from a lesion or dysfunction within the nervous system; the specific
mechanisms that elicit neuropathic pain symptoms are the subject of ongoing research. It is …

Purpose Routine follow-up of adult cancer survivors is an important clinical and health service
issue. Because of a lack of evidence supporting advantages of long-term follow-up care in …